Short term trials with surrogate measures instead of hard outcomes are often used to study chronic diseases. The effects of an intervention may, however, take time to develop and persist after ...

Unlike existing treatments that target pathways like glucagon-like peptide 1 (GLP-1), BRP operates through ... to predict cleavage sites in secreted human proteins. The algorithm analyzed ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for ... of cognitive impairment and dementia syndromes. Focusing on evidence from human studies, we highlight how brain energy ...

The 2025 Breakthrough Prize in Life Sciences has been awarded to five scientists for the discovery and characterization of the hormone glucagon-like peptide-1, or GLP-1 — findings ... alter our ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists ... given the heterogeneity of ...

A further case study is the activation of the class B1 GPCR glucagon-like peptide-1 receptor (GLP-1R ... To our knowledge, this is the first time the whole sequence of events leading from an inactive ...

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with ...

Expanding Medicare coverage for glucagon-like peptide 1 (GLP-1) receptor agonists could significantly reduce obesity-related ...

Among US adults without diabetes, the use of GLP-1 RAs increased from 2018 to 2022, reaching annual prevalence of 0.4% in 2022.

Topline data were announced from a phase 3 trial evaluating orforglipron in adults with T2D and inadequate glycemic control with diet and exercise alone.